Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Monoclonal Antibodies Competitive Landscape Report 2026: Comprehensive Insights About 180+ Companies and 230+ Drugs by Company, Product, Stage of Development, Route of Administration, Molecule Type

globenewswire.com
BMY Bristol Myers Squibb is mentioned as a biopharmaceutical powerhouse with its flagship PD-1 inhibitor, OPDIVO, approved worldwide for diverse cancers. The article highlights its focus on innovative cancer treatments. GSK GSK is identified as a biopharma leader prioritizing innovation in vaccines and specialty medicines, particularly in oncology and immunology. Their product NUCALA is mentioned for treating eosinophilic inflammation. NVS Novartis is highlighted for being at the forefront with Ianalumab, a monoclonal antibody targeting B cell activation in advanced phases for autoimmune and inflammatory diseases. They are also mentioned for Iscalimab in mid-stage products. NVO Novo Nordisk is noted for developing Ziltivekimab, aimed at cardiovascular risk reduction in kidney disease patients, indicating a focus on chronic ailments.

Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The "Monoclonal Antibodies - Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering.

The report offers a detailed analysis of the space encompassing 180+ companies and over 230 drugs. It assesses therapeutics based on product type, stage of development, route of administration, and molecule type. The report also identifies inactive pipeline products globally.

Monoclonal Antibodies (mAbs) represent a significant advancement in immunotherapy. They offer targeted treatment, especially in oncology, by honing in on specific antigens linked to tumor growth. Key types of mAbs include human, murine, humanized, and chimeric, each with distinct derivations from human and mouse proteins.

Structurally, mAbs consist of a Y-shaped composition, allowing for high stability and flexibility. Their inherent precision aids in exploiting immune response through ADCC and CDC processes, making them suitable for advanced therapeutic interventions. Most clinical mAbs are IgG-based, reflecting their robust efficacy.

As therapeutic mAbs gain traction, challenges remain, particularly concerning antigen specificity. However, advances in stereo-specific mAbs targeting antigen conformational structures promise a more robust approach to therapeutic applications, potentially reshaping treatment paradigms.

Report Highlights

Company and Product Profiles

Bristol Myers Squibb (BMS): BMS is a biopharmaceutical powerhouse focusing on innovative cancer treatments. OPDIVO, their flagship PD-1 inhibitor, is approved worldwide for diverse cancers, leveraging the immune system to combat tumors.

GSK: A biopharma leader, prioritizing innovation in vaccines and specialty medicines, particularly in oncology and immunology. Their product, NUCALA, targets eosinophilic inflammation, approved for various conditions worldwide.

Pipeline Innovations

Novartis: At the forefront with Ianalumab, a monoclonal antibody targeting B cell activation, currently in advanced phases for autoimmune and inflammatory diseases.

Novo Nordisk: Developing Ziltivekimab, aimed at cardiovascular risk reduction in kidney disease patients, highlighting their focus on chronic ailments.

Disc Medicine: Disc Medicine advances treatments addressing anemia through DISC-0974, targeting key biological pathways and already showing promising early results.

Strategic Collaborations & Competitive Analysis

This report delivers comprehensive assessments of drug collaborations, agreements, licensing, and acquisitions. It highlights recent industry trends, emerging therapies, and potential future pathways for monoclonal antibodies.

Key Players and Products

Key Topics Covered:

Introduction

Executive Summary

Monoclonal antibodies: Overview

Monoclonal antibodies - Analytical Perspective: In-depth Commercial Assessment

Competitive Landscape

Therapeutic Assessment

Monoclonal antibodies: Company and Product Profiles (Marketed Therapies)

Bristol-Myers Squibb

OPDIVO

Monoclonal antibodies: Company and Product Profiles (Pipeline Therapies)

Late Stage Products (Phase III)

Novartis

Ianalumab

Mid Stage Products (Phase II)

Novartis

Iscalimab

Early Stage Products (Phase I/II)

Chinook Therapeutics

BION-1301

Preclinical and Discovery Stage Products

Company Name

Product Name

Inactive Products

Monoclonal antibodies- Unmet needs

Monoclonal antibodies - Market drivers and barriers

Appendix

Companies Featured

For more information about this report visit https://www.researchandmarkets.com/r/5amsus

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.